More than a third of high-risk leukemia patients respond to an experimental new drug
'It caught us by surprise, how well this works.' -- Mark Levis, M.D., Ph.D.
2012-12-09
(Press-News.org) A new drug for patients with acute myeloid leukemia (AML) marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial. In more than a third of participants, the leukemia was completely cleared from the bone marrow, and as a result, many of these patients were able to undergo potentially curative bone marrow transplants, according to investigators at the Johns Hopkins Kimmel Cancer Center and nine other academic medical centers around the world. Many of the participants who did well with the new drug, quizartinib or AC220, had failed to respond to prior therapies.
"We can put two-thirds to three-quarters of adults with AML into remission with chemotherapy, but there's a 50 percent chance of the disease coming back, which usually ends up being fatal," says Mark Levis, M.D., Ph.D., lead investigator on the study and associate professor of oncology and medicine at Johns Hopkins. "Many patients in this trial were able to go on to receive a potentially life-saving bone marrow transplant. It caught us by surprise how well it works," he adds.
A report on the study is expected to be presented December 9 during a press briefing at the American Society of Hematology's annual meeting in Atlanta.
For the clinical trial, researchers enrolled 137 AML patients, the majority of whom carried a mutation in a gene called FLT3-ITD within their leukemia cells. The FLT3 gene produces an enzyme that signals bone marrow stem cells to divide and replenish. In about a quarter of patients with AML, the disease mutates FLT3 so that the enzyme stays on permanently, causing rapid growth of leukemia cells and making the condition harder to treat.
"A FLT3-ITD mutation tells us that, typically, patients will need very intensive chemotherapy just to achieve a remission, and then the disease will regrow quickly," Levis says. "So, we have learned to try to perform a bone marrow transplant soon after we get the patient into remission, before the cancer relapses."
Quizartinib, which blocks the FLT3 enzyme, and is available in liquid oral form, is so potent that it typically starts working in just two days, Levis says, though it may take up to 60 days to completely eliminate AML cells from the bone marrow.
At Johns Hopkins and nine other centers, the 137 AML recruited patients received quizartinib at a starting dose of 90 mg/day for women and 135 mg/day for men, and were treated continuously during 28-day cycles. Study participants either had relapsed, did not respond to second-line chemotherapy or had relapsed following hematopoietic stem cell transplantation.
Forty-four percent (44) of the 99 participants with a FLT3-ITD mutation experienced some form of complete remission, typically one in which the leukemia was cleared from the bone marrow, but the patient still needed blood and platelet transfusions. Thirty-four percent (13) of the 38 participants in whom the FLT3-ITD mutation was not detectable experienced this type of response.
The most common side effects with quizartinib were nausea (38 percent), anemia (29 percent), QT prolongation (an abnormality found on an EKG; 26 percent), vomiting (26 percent), febrile neutropenia (development of fever in someone with low white blood cell count; 25 percent), diarrhea (20 percent), and fatigue (20 percent). Fourteen patients (10 percent) experienced side effects severe enough to discontinue taking the drug. Investigators have been testing lower doses of the medication since the trial to reduce side effects, Levis says.
Long-term survival from the therapy is still unknown, Levis says, but of the group of 137 patients, 47 (34 percent) were able to receive a transplant after responding to quizartinib. Some of these patients have survived two years after treatment with no disease recurrence.
Based on results, the company that makes the drug, Ambit Biosciences, is planning larger Phase III trials, in which patients who have the FLT3 mutation will receive either quizartinib or chemotherapy after random grouping. Meanwhile, Levis and other physicians are continuing to study the drug in a clinical trial testing lower doses.
###
The centers participating in the trial were: Abramson Cancer Center, University of Pennsylvania; Hôpital Saint-Louis, Université Paris; University Hospital of Ulm, Germany; Goethe University of Frankfurt, Germany; Hopital de Versailles, Le Chesnay, France; Bologna University School of Medicine, Italy; University of Washington, Seattle; Cardiff University School of Medicine, United Kingdom; University of Texas MD Anderson Cancer Center, Houston.
Levis is a consultant for Ambit Biosciences Inc., manufacturers of quizartinib (AC220). This relationship has been disclosed and is under the management of the Johns Hopkins University School of Medicine Conflict of Interest Committee.
ELSE PRESS RELEASES FROM THIS DATE:
Studies challenge standards to improve treatment outcomes for patients with clotting disorders
2012-12-09
(ATLANTA, December 8, 2012) – Studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH) examine current treatment standards for patients with clotting disorders in an effort to improve outcomes. The studies evaluate long-held treatment standards and whether modifications in intensity and duration of therapy may offer equally effective outcomes while reducing toxicities and relapse rates.
Although significant advances have been made in delivering new and improved therapies for clotting disorders, treatment still presents challenges; ...
Pre-clinical data shows Angiocidin effective against leukemia
2012-12-09
Angiocidin, a novel tumor-inhibiting protein, has been shown to reduce acute myeloid leukemia (AML) cells in vivo by almost two-thirds in pre-clinical experiments.
George P. Tuszynski, a professor of neuroscience in Temple University's School of Medicine who discovered Angiocidin, will present the findings during the American Society of Hematology's national meeting in Atlanta on Dec. 9.
AML causes certain white blood cells to stop maturing, resulting in their uncontrolled proliferation, which can lead to suppression of the immune system and often fatal secondary problems ...
Grizzly Beatz Provides High Quality Rap Instrumentals Across a Range of Genres
2012-12-09
Grizzly Beatz is an up-and-coming hip-hop producer that is been able to produce high-quality instrumentals for a range of different artists. Recently, Grizzly Beatz launch their own website and blog, allowing individuals to logon, listen to the beats that are available on the website, and then make a purchase for as little as $12. Their goal to provide high-quality beats, at a reasonable price for up-and-coming artists, has made them one of the premier online rep production services. With hundreds of different beats available, both on their website for purchase, as well ...
JBatch It v6 Redesigned to Support both 32 Bit and 64 Bit Windows 8
2012-12-09
iRedSoft Technology Inc announce the immediate release of JBatch It v6. JBatch It is a Batch Image Processor which takes away the mundane task of resizing, adding text caption, applying effects, fixing photo orientation and renaming image filenames. This would help increase productivity and minimizing mistakes made when handling large volume of digital photos. It supports JPEG, Single Page TIFF, PNG, BMP and GIF format.
JBatch It v6 is a totally redesigned version of the application so as to support natively both the 32 Bit and 64 Bit Windows including the new Windows ...
Santa Brings Christmas Trees & Catnip to Sunrise Village This Holiday Season
2012-12-09
This year Santa is bringing Christmas trees and catnip to Sunrise Village, just a few of the many holiday happenings at the Puyallup shopping center. In addition to holiday sales and individual merchant events, Sunrise Village's holiday activities include:
Nov. 23 til gone (9 am - 9 pm): Puyallup South Hill Lions Club Christmas Tree Sales
Now through Dec. 16: Secret Santa Toy Drive at Sleep Country USA
Dec. 8-9 (10 am - 4 pm): Santa Claws Pet Photos & Pet Adoptions at PetSmart
Dec. 9 (9 am to Noon): Breakfast with Santa at The RAM
Dec. 10 (6 - 9 pm): ...
Livewire Concepts, Inc. Raises Money For Kids!
2012-12-09
Livewire Concepts, Inc recently raised over $600 for Operation Smile, a nonprofit organization that performs surgeries for children born in third world countries with cleft palettes and other facial deformities.
The cost of each surgery is $240, which is often too much for struggling families in impoverished nations The event was held at McFaddens in the Power and Light District. A raffle was held with giveaways from several local shops and restaurants as well as drink and food specials for all attending guests. The president of Livewire Concepts, C.J. Suggs said, "It's ...
Toddy Gear Celebrates the Holidays with Six New Seasonal Designs
2012-12-09
Toddy Gear is now selling its popular Toddy Smart Cloth and Wedge for a limited time featuring whimsical designs from the new "Season's Cleanings" collection. Peppo, Midnight Moose, and Winter Wonderland Smart Cloths bring the festive side to cleaning electronics screens, while Santa, Elf, and Rudolph Wedges will cradle your hand-held devices with style. These functional and fashionable microfiber cleaning products make wonderful stocking stuffers for family, friends, and coworkers.
The Wedge is an innovative and practical accessory for a number of electronic ...
"It's Your Turn to Answer the Call" VoiceNation's Job Fair at Goodwill a Huge Success
2012-12-09
of over 120 job seekers at their recent job fair held at Goodwill of North Georgia's Oakwood Career Center.
The job fair was part of VoiceNation's recruitment campaign entitled "It's Your Turn to Answer the Call". The company is looking to fulfill Customer Service Representative positions for full and part-time shifts at their expanding call center in Buford. VoiceNation is one of the fastest growing answering services in the industry. Customer Service Representatives are needed to answer inbound calls, take orders, screen calls and provide event registration ...
AVAD's 2013 Product Catalog Now Available
2012-12-09
AVAD LLC, one of North America's leading providers of custom electronics, has announced the availability of the all-new 2013 AVAD Product Catalog. The 172-page, full-color catalog features all of the latest products and technologies from the leading suppliers in the residential and commercial electronics industries.
In addition to the comprehensive product details and specifications that customers have come to expect from AVAD's annual catalog, the 2013 catalog features the best brands and products in the company's history. The new guide, which will be available in printed ...
Contractor Management Services (CMS) Gains Exposure Through NFIB Membership
2012-12-09
Contractor Management Services (CMS), the nation's full-service leader in Independent Contractor Management (ICM), has formally announced it has been accepted as a member in the National Federation of Independent Businesses (NFIB), a non-profit organization that represents the interests of its member small businesses in Washington D.C. and all 50 state capitals.
The NFIB membership gives CMS a business-centric venue to connect with small businesses potentially facing issues such as worker misclassification. Members of CMS' senior management team will seek opportunities ...
LAST 30 PRESS RELEASES:
New research boosts future whooping cough vaccines
Mechanistic understanding could enable better fast-charging batteries
No bones about it: new details about skeletal cell aging revealed
UNM scientists discover how nanoparticles of toxic metal used in MRI scans infiltrate human tissue
UMaine research examines best methods for growing Atlantic sea scallops
Medical cannabis could speed recovery, especially at community recovery homes
Study assesses U.S. image amid weakening of democracy
Two scientific researchers to receive 2025 Ralph L. Sacco Scholarships for Brain Health
Researchers improve chemical reaction that underpins products from foods to fuels
Texas Tech to develop semiconductor power devices through $6 million grant
Novel genomic screening tool enables precision reverse-engineering of genetic programming in cells
Hot Schrödinger cat states created
How cells repair their power plants
Oxygen is running low in inland waters—and humans are to blame
ACP’s Best Practice Advice addresses use of cannabis, cannabinoids for chronic noncancer pain
Beyond photorespiration: A systematic approach to unlocking enhanced plant productivity
How a small number of mutations can fuel outbreaks of western equine encephalitis virus
Exposure to wildfire smoke linked with worsening mental health conditions
Research uncovers hidden spread of one of the most common hospital-associated infections
Many older adults send their doctors portal messages, but who pays?
Fine particulate matter from 2020 California wildfires and mental health–related emergency department visits
Gender inequity in institutional leadership roles in US academic medical centers
Pancreatic cells ‘remember’ epigenetic precancerous marks without genetic sequence mutations
Rare combination of ovarian tumors found in one patient
AI-driven clinical recommendations may aid physician decision making to improve quality of care
Artificial intelligence has potential to aid physician decisions during virtual urgent care
ACP and Annals of Internal Medicine present breaking scientific news at ACP’s Internal Medicine Meeting 2025
New study reveals polymers with flawed fillers boost heat transfer in plastics
Signs identified that precede sudden arrhythmic death syndrome in young people
Discovery of bacteria's defence against viruses becomes a piece of the puzzle against resistance
[Press-News.org] More than a third of high-risk leukemia patients respond to an experimental new drug'It caught us by surprise, how well this works.' -- Mark Levis, M.D., Ph.D.